ScreenerHero
VCYTVeracyte, Inc.
NAS · US · Healthcare · Diagnostics & Research · veracyte.com
41.42USD-1.83%Mkt Cap: 3.39B $P/E: 30.14

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for …

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group Ltd
$46.70BUSDP/E 37.9
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.64BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMerieux S.A.
$9.51BUSDP/E 19.0
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8
TWST
Twist Bioscience Corp.
$8.93BUSD

Key Statistics

Company
Market Cap3.39B $
Enterprise Value2.91B $
Revenue (TTM)561.90M $
Gross Profit362.53M $
Net Income (TTM)66.35M $
Revenue/Share7.081 USD
Last Price41.42 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees755
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS92337F1075
Valuation
P/E (Trailing)30.14
P/E (Forward)21.45
PEG—
EV/EBITDA25.67
EV/Revenue5.19
P/S5.98
P/B2.42
EPS (TTM)1.39
EPS (Forward)1.95
52W Range
28.2540% of range60.91
52W High60.91 USD
52W Low28.25 USD
Profitability
Gross Margin70.10%
Oper. Margin15.29%
EBITDA Margin20.20%
Profit Margin12.83%
ROE5.07%
ROA4.72%
Growth
Revenue Growth15.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF136.31M $
CapEx (TTM)9.68M $
FCF Margin18.91%
FCF Yield3.13%
Net Debt-445.13M $
Net Debt/EBITDA-3.92
Balance Sheet
Debt/Equity0.03
Current Ratio9.16
Quick Ratio8.60
Book Value/Sh17.28 USD
Cash/Share6.036 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)57.82 USD
Upside (mean)+39.6%
Target Range44.00 USD – 70.00 USD
$44.00+39.6% to mean$70.00
# Analysts11
Ownership
Shares Out.80.39M
Float79.88M
Insiders0.54%
Institutions113.45%
Short Interest
Short Ratio5.5d
Short % Float10.08%
Short % Out.8.53%
Shares Short6.86M
Short (prev mo.)6.72M
Technical
SMA 5052.52 (-21.1%)
SMA 20042.49 (-2.5%)
Beta1.94
S&P 52W Chg18.16%
Avg Vol (30d)1.23M
Avg Vol (10d)1.16M
Technical Indicators
RSI (14)32.7
MACD-3.3608
MACD Signal-2.5440
MACD Hist.-0.8167
BB Upper61.62 USD
BB Middle49.09 USD
BB Lower36.56 USD
BB Width51.04%
ATR (14)2.765 USD
Vol Ratio (20d)1.37x